Christina D. Chambers, PhD

Professor
University of California, San Diego
UCSD
La Jolla, California, United States

Dr. Christina Chambers is a Professor in the School of Medicine at UC San Diego. She is Co-Director of the Center for Better Beginnings, Program Director of MotherToBaby, a service providing evidence-based information on exposures during pregnancy and lactation, and is Program Director of Mommy’s Milk, a human milk biorepository for research.
Dr. Chambers leads a number of national and international complex longitudinal cohort studies and clinical trials of prenatal exposures and child health and development. Her research has been instrumental in identifying previously unrecognized human teratogens, as well as ruling out substantial risk for medications and vaccines.

AstraZeneca (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Celgene (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Genzyme Sanofi-Aventis (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Gerber Foundation (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Gilead (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)GlaxoSmithKline (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Hoffman La-Roche-Genentech (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Janssen Pharmaceuticals (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Pfizer, Inc (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Regeneron (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Sanofi (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Sun Pharma Global FZE (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Takeda Pharmaceutical Company Limited (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)UCB Pharma (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Post-authorization Regulatory Strategies to Evaluate Drug Safety in Pregnancy: How to Optimize the Design of Registries & Database Studies

  Friday, August 26, 2022
  10:30 AM – 12:00 PM CEST

• Meeting the Need for Research on Drug Safety During Lactation: An Overview of Approaches

  Friday, August 26, 2022
  3:30 PM – 5:00 PM CEST

• Quantification of Medication-mediated Effects on Pregnancy Outcome in Women with Rheumatic Conditions

  Sunday, August 28, 2022
  9:45 AM – 10:00 AM CEST

• Associations of prenatal exposure to non-steroidal anti-inflammatory drugs with preterm birth and small-for-gestational age among women with autoimmune disorders

  Sunday, August 28, 2022
  2:45 PM – 2:50 PM CEST